Investment Rating - The report assigns a "Buy" rating for the company, marking the first coverage of the stock [9]. Core Views - The company experienced a revenue decline of 15.66% year-on-year in 2024, with total revenue reaching 1.861 billion yuan and a net profit of 340 million yuan, down 20.01% year-on-year [2][9]. - Despite short-term pressures in the coal industry, long-term resilience is expected due to policy support and increasing demand for intelligent mining solutions [2]. - The company is positioned as a leader in the unmanned intelligent mining control sector, benefiting from the ongoing industry upgrade trend [2][3]. Summary by Sections Industry Outlook - The coal industry is facing short-term challenges due to fluctuations in coal prices, but long-term demand is supported by capacity release and policy backing [2]. - The production of raw coal in China reached 4.76 billion tons in 2024, an increase of 1.3% year-on-year, marking a historical high [2]. Technology and Innovation - The company has established high technical barriers with 17 categories and 63 core technologies, including advancements in unmanned mining processes [3]. - R&D investment for 2024 is projected at 155 million yuan, representing 8.32% of revenue, with a focus on enhancing technological capabilities [7]. International Strategy - The company is expanding its international presence, achieving nearly 30 million yuan in overseas sales in 2024, a record high [8]. - Significant partnerships have been established with international clients, including a notable contract with a major Russian coal producer [8]. Financial Projections - Revenue forecasts for 2025-2027 are 1.822 billion yuan, 1.997 billion yuan, and 2.118 billion yuan, respectively, with expected EPS of 0.87, 0.98, and 1.08 yuan [9][11]. - The company anticipates a recovery in performance driven by international expansion and domestic policy support [9].

技术平台领先，合作窗口提前 证 券 研 究 报 告 行业周报 医药行业周报 投资评级： 报告日期： 推荐 维持 2025年03月23日 ◼ 分析师：胡博新 ◼ SAC编号：S1050522120002 医 药 行 业 观 点 1 . 新技术平台更为MNC所青睐，合作窗口提前 2025年3月21日，和铂医药与阿斯利康达成一项全球战略合作，此次战略合作内容涵盖基于和铂医药专有的Harbour Mice® 全人源抗体技术平台在多治疗领域的多项目授权许可协议，以及阿斯利康对和铂医药的1.05亿美元股权投资。此前，阿斯 利康合作的国内项目主要以临床阶段产品为主，此次合作项目处于早期，可见MNC对中国biotech的新技术平台的高度认可。 随着更多合作项目推向临床，持续验证结果，MNC对中国biotech的信任也逐步提高。投资换股的方式，也意味深入合作的 进一步绑定，进一步扩宽合作项目领域。2025年全球新药BD依然保持火热，据DealForma数据显示，2024年约31%的大型 跨国药企引进的创新药候选分子来自中国。在抗体、ADC、双抗等领域，中国biotech从研发的初始就建立起技术的优势， 而且不断尝试探索新靶点新 ...

2025 年 03 月 22 日 研 究 报 告 背靠施耐德拓展数据中心业务，厦门国资入主助 力公司新成长 买入(首次) 事件 | 分析师：任春阳 | S1050521110006 | | --- | --- | | rency@cfsc.com.cn | | | 分析师：傅鸿浩 | S1050521120004 | | fuhh@cfsc.com.cn | | | 分析师：杜飞 | S1050523070001 | | dufei2@cfsc.com.cn | | | 基本数据 | 2025-03-21 | | --- | --- | | 当前股价（元） | 14.45 | | 总市值（亿元） | 48 | | 总股本（百万股） | 333 | | 流通股本（百万股） | 255 | | 52 周价格范围（元） | 9.05-17.42 | | 日均成交额（百万元） | 152.35 | 市场表现 —电工合金（300697.SZ）公司事件点评报告 3 月 21 日晚公司发布 2024 年报：报告期内公司实现营收 25.93 亿元，同比增长 8.37%，实现归母净利润 1.31 亿元， 同比下降 3.62%。 ...

2025 年 03 月 20 日 发布激励计划，彰显发展信心 买入(维持) 事件 | 基本数据 | 2025-03-20 | | --- | --- | | 当前股价（元） | 16.32 | | 总市值（亿元） | 93 | | 总股本（百万股） | 569 | | 流通股本（百万股） | 569 | | 52 周价格范围（元） | 13.09-18.56 | | 日均成交额（百万元） | 61.21 | 市场表现 -30 -20 -10 0 10 20 30 (%) 广州酒家 沪深300 资料来源：Wind，华鑫证券研究 相关研究 | 分析师：孙山山 | S1050521110005 | | --- | --- | | sunss@cfsc.com.cn | | | 联系人：张倩 | S1050124070037 | | zhangqian@cfsc.com.cn | | 1、《广州酒家（603043）：营收增 速稳健，餐饮业务势能延续》2024- 09-08 2、《广州酒家（603043）：营收规 模稳健增长，餐饮业务贡献增量》 2024-04-26 3、《广州酒家（603043）：月饼平 稳放量，餐饮 ...

Investment Rating - The report maintains a "Buy" investment rating for the company [10] Core Views - The company is expected to see significant revenue growth in 2024, with a projected operating income of 135.85 billion yuan, representing a year-on-year increase of 67.60% [4] - The company has successfully reduced gold mining costs, with the average cost per gram dropping to 145.40 yuan in 2024 from 176.42 yuan in 2023 [6] - The company is expanding its operations internationally, having acquired 100% of Osino Resources Corp. for 1.90 CAD per share, which includes the Twin Hills gold project in Namibia [7] Summary by Sections Financial Performance - In Q4 2024, the company reported a revenue of 15.14 billion yuan, a year-on-year increase of 49.81% [5] - The net profit attributable to shareholders for Q4 2024 was 4.46 billion yuan, up 45.69% year-on-year [5] Cost Management - The company produced 8.04 tons of gold in 2024, with a forecast of at least 8 tons for 2025 [6] - The average gold price in Shanghai for 2024 was 556 yuan per gram, a 23.87% increase from 2023 [6] Future Projections - Revenue forecasts for 2025, 2026, and 2027 are 108.99 billion yuan, 122.10 billion yuan, and 135.64 billion yuan, respectively [10] - The net profit attributable to shareholders is projected to be 31.00 billion yuan, 37.33 billion yuan, and 43.67 billion yuan for the same years [10]

Investment Rating - The report maintains a "Buy" investment rating for the company [9] Core Views - The company has launched a new stock option and restricted stock incentive plan, reflecting its confidence in future development [5] - The company aims for a revenue growth rate of no less than 16%/28%/40.85% from 2025 to 2027, with a target return on equity (ROE) of at least 12.58%/12.91%/13.17% during the same period [5] - The mooncake business is expected to benefit from both internal and external drivers, while the restaurant segment is projected to maintain steady growth through store expansion [6] - The company is leveraging its first-mover advantage in Guangdong to strengthen its market share in mooncakes and frozen products, with a focus on expanding into markets outside the province [7] Financial Forecasts - The company's main revenue is projected to grow from 4,901 million yuan in 2023 to 6,227 million yuan in 2026, reflecting a growth rate of 19.2% in 2023 and 8.9% in 2026 [11] - The diluted earnings per share (EPS) are adjusted to 0.91, 1.04, and 1.15 yuan for 2024, 2025, and 2026 respectively, with corresponding price-to-earnings (PE) ratios of 18, 16, and 14 times [9][11] - The company anticipates a net profit of 626 million yuan in 2025, up from 550 million yuan in 2023, indicating a growth rate of 14.0% [11]

Investment Rating - The report maintains a "Buy" investment rating for the company [10] Core Views - The company is expected to see significant revenue growth in 2024, with a projected operating income of 13.585 billion yuan, representing a year-on-year increase of 67.6% [4][12] - The company has successfully reduced gold mining costs, with the average cost per gram dropping from 176.42 yuan in 2023 to 145.40 yuan in 2024 [6] - The company has initiated overseas gold mine acquisitions, specifically acquiring 100% of Osino Resources Corp. for 1.90 CAD per share, which includes the Twin Hills gold project in Namibia [7] Summary by Sections Financial Performance - In Q4 2024, the company reported a revenue of 1.514 billion yuan, a year-on-year increase of 49.81% [5] - The net profit attributable to shareholders for Q4 2024 was 446 million yuan, up 45.69% year-on-year [5] Cost Management - The company produced 8.04 tons of gold in 2024, with a sales volume of 8.05 tons, and expects to maintain production levels above 8 tons in 2025 [6] - The average gold price in 2024 was 556 yuan per gram, reflecting a 23.87% increase from 2023 [6] Profit Forecast - The forecast for operating income from 2025 to 2027 is 108.99 billion yuan, 122.10 billion yuan, and 135.64 billion yuan respectively [10] - The projected net profit attributable to shareholders for the same period is 31.00 billion yuan, 37.33 billion yuan, and 43.67 billion yuan respectively [10]

2025 年 03 月 20 日 Genio 720 和 Genio 520 联合发布，视频生成模 型 Open-Sora 2.0 发布 —计算机行业周报 推荐(维持) 投资要点 分析师：宝幼琛 S1050521110002 baoyc@cfsc.com.cn 行业相对表现 表现 1M 3M 12M 计算机(申万) -0.2 8.9 27.8 沪深 300 2.1 2.1 11.8 市场表现 相关研究 1、《计算机行业点评报告：阿里云 QwQ-32B 开源模型全球首发，引领超 低密度智能与端侧生态范式革命》 2025-03-11 2、《计算机行业点评报告：智能体 Manus 震撼发布，开启自主执行与跨 领域协同新纪元》2025-03-11 3、《计算机行业周报：全球首个混 合 推 理 模 型 Claude3.7Sonnet 发 布，高情商模型 GPT-4.5 问世》 2025-03-04 ▌算力：算力租赁价格平稳，Genio 720 和 Genio 520 联合发布 2025 年 3 月 12 日， 在国际嵌入式展（EMBEDDED WORLD） 上，联发科技（MediaTek）发布高性能边缘 AI 物联网芯 ...

Investment Rating - The report maintains a "Buy" investment rating for the company [10] Core Views - The company achieved a revenue of 1.182 billion yuan in 2024, representing a year-on-year growth of 22%, primarily driven by the launch of new products [5] - The net profit attributable to shareholders reached 157 million yuan, up 35% year-on-year, with a significant increase in the fourth quarter [5] - The company is expected to continue benefiting from channel expansion and product innovation, particularly in the bone-free duck feet segment [10] Summary by Sections Financial Performance - In 2024, the company reported a revenue of 1.182 billion yuan, a 22% increase year-on-year, and a net profit of 157 million yuan, reflecting a 35% growth [5] - The fourth quarter of 2024 saw a revenue of 296 million yuan, up 43% year-on-year, and a net profit of 36 million yuan, which is a 258% increase [5] - The gross margin improved to 25.69% in Q4 2024, with expectations for continued optimization in 2025 due to falling raw material prices [5] Product Performance - Revenue from the main products, including bubble chicken feet, skin jelly, and chicken wings, was 785 million yuan, 93 million yuan, and 48 million yuan respectively, with growth rates of 9%, 6%, and 24% [6] - The company plans to focus on bone-free products and enhance existing flavors, anticipating sustained growth in product lines [6] Channel Development - Online and offline channel revenues in Q4 2024 were 24 million yuan and 267 million yuan, respectively, with online sales growing by 133% [7] - The company is leveraging the Sam's Club channel and e-commerce platforms to drive sales growth, while traditional supermarket channels face challenges [9] Earnings Forecast - The company is expected to maintain strong growth, with projected EPS of 0.43 yuan, 0.50 yuan, and 0.58 yuan for 2025, 2026, and 2027 respectively [10] - The current stock price corresponds to a PE ratio of 22, 19, and 17 for the years 2025, 2026, and 2027 [10]

Investment Rating - The report maintains a "Buy" investment rating for the company [10] Core Views - The company achieved a revenue of 1.182 billion yuan in 2024, representing a year-on-year growth of 22%, primarily driven by the launch of new products [5] - The net profit attributable to shareholders reached 157 million yuan, up 35% year-on-year, with a significant increase in the fourth quarter [5] - The company is expected to continue benefiting from channel expansion and product innovation, particularly in the bone-free duck feet segment [10] Summary by Sections Financial Performance - In 2024, the company reported a revenue of 1.182 billion yuan, a 22% increase year-on-year, and a net profit of 157 million yuan, a 35% increase [5] - The fourth quarter saw a revenue of 296 million yuan, up 43% year-on-year, and a net profit of 36 million yuan, up 258% [5] - The gross margin improved to 25.69% in Q4 2024, with expectations for continued optimization in 2025 [5] Product Performance - Revenue from main products such as bubble chicken feet, skin jelly, and chicken wings was 785 million yuan, 93 million yuan, and 48 million yuan respectively, with growth rates of 9%, 6%, and 24% [6] - The company plans to focus on bone-free products and enhance existing flavors, anticipating sustained growth in product lines [6] Channel Development - Online and offline channel revenues in Q4 2024 were 24 million yuan and 267 million yuan, reflecting growth rates of 133% and 36% respectively [7] - The company is leveraging platforms like Douyin for product promotion and expects continued growth in e-commerce channels [7] Regional Performance - Revenue growth varied by region, with significant increases in Southwest and East China, while some regions experienced declines [9] - The company aims to strengthen its brand presence in its core markets [9] Earnings Forecast - The company is projected to achieve EPS of 0.43 yuan, 0.50 yuan, and 0.58 yuan for 2025, 2026, and 2027 respectively, with corresponding PE ratios of 22, 19, and 17 [10]